Cargando…

A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy

Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical neglected tropical disease. Specific immunity promotes acute phase survival. Nevertheless, one-third of CD patients develop chronic chagasic cardiomyopathy (CCC) associated with parasite persistence and immunological u...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Isabela Resende, Vilar-Pereira, Glaucia, Marques, Virgínia, da Silva, Andrea Alice, Caetano, Bráulia, Moreira, Otacilio Cruz, Machado, Alexandre Vieira, Bruna-Romero, Oscar, Rodrigues, Maurício Martins, Gazzinelli, Ricardo Tostes, Lannes-Vieira, Joseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305326/
https://www.ncbi.nlm.nih.gov/pubmed/25617628
http://dx.doi.org/10.1371/journal.ppat.1004594
_version_ 1782354219957747712
author Pereira, Isabela Resende
Vilar-Pereira, Glaucia
Marques, Virgínia
da Silva, Andrea Alice
Caetano, Bráulia
Moreira, Otacilio Cruz
Machado, Alexandre Vieira
Bruna-Romero, Oscar
Rodrigues, Maurício Martins
Gazzinelli, Ricardo Tostes
Lannes-Vieira, Joseli
author_facet Pereira, Isabela Resende
Vilar-Pereira, Glaucia
Marques, Virgínia
da Silva, Andrea Alice
Caetano, Bráulia
Moreira, Otacilio Cruz
Machado, Alexandre Vieira
Bruna-Romero, Oscar
Rodrigues, Maurício Martins
Gazzinelli, Ricardo Tostes
Lannes-Vieira, Joseli
author_sort Pereira, Isabela Resende
collection PubMed
description Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical neglected tropical disease. Specific immunity promotes acute phase survival. Nevertheless, one-third of CD patients develop chronic chagasic cardiomyopathy (CCC) associated with parasite persistence and immunological unbalance. Currently, the therapeutic management of patients only mitigates CCC symptoms. Therefore, a vaccine arises as an alternative to stimulate protective immunity and thereby prevent, delay progression and even reverse CCC. We examined this hypothesis by vaccinating mice with replication-defective human Type 5 recombinant adenoviruses (rAd) carrying sequences of amastigote surface protein-2 (rAdASP2) and trans-sialidase (rAdTS) T. cruzi antigens. For prophylactic vaccination, naïve C57BL/6 mice were immunized with rAdASP2+rAdTS (rAdVax) using a homologous prime/boost protocol before challenge with the Colombian strain. For therapeutic vaccination, rAdVax administration was initiated at 120 days post-infection (dpi), when mice were afflicted by CCC. Mice were analyzed for electrical abnormalities, immune response and cardiac parasitism and tissue damage. Prophylactic immunization with rAdVax induced antibodies and H-2K(b)-restricted cytotoxic and interferon (IFN)γ-producing CD8(+) T-cells, reduced acute heart parasitism and electrical abnormalities in the chronic phase. Therapeutic vaccination increased survival and reduced electrical abnormalities after the prime (analysis at 160 dpi) and the boost (analysis at 180 and 230 dpi). Post-therapy mice exhibited less heart injury and electrical abnormalities compared with pre-therapy mice. rAdVax therapeutic vaccination preserved specific IFNγ-mediated immunity but reduced the response to polyclonal stimuli (anti-CD3 plus anti-CD28), CD107a(+) CD8(+) T-cell frequency and plasma nitric oxide (NO) levels. Moreover, therapeutic rAdVax reshaped immunity in the heart tissue as reduced the number of perforin+ cells, preserved the number of IFNγ(+) cells, increased the expression of IFNγ mRNA but reduced inducible NO synthase mRNA. Vaccine-based immunostimulation with rAd might offer a rational alternative for re-programming the immune response to preserve and, moreover, recover tissue injury in Chagas’ heart disease.
format Online
Article
Text
id pubmed-4305326
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43053262015-01-30 A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy Pereira, Isabela Resende Vilar-Pereira, Glaucia Marques, Virgínia da Silva, Andrea Alice Caetano, Bráulia Moreira, Otacilio Cruz Machado, Alexandre Vieira Bruna-Romero, Oscar Rodrigues, Maurício Martins Gazzinelli, Ricardo Tostes Lannes-Vieira, Joseli PLoS Pathog Research Article Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical neglected tropical disease. Specific immunity promotes acute phase survival. Nevertheless, one-third of CD patients develop chronic chagasic cardiomyopathy (CCC) associated with parasite persistence and immunological unbalance. Currently, the therapeutic management of patients only mitigates CCC symptoms. Therefore, a vaccine arises as an alternative to stimulate protective immunity and thereby prevent, delay progression and even reverse CCC. We examined this hypothesis by vaccinating mice with replication-defective human Type 5 recombinant adenoviruses (rAd) carrying sequences of amastigote surface protein-2 (rAdASP2) and trans-sialidase (rAdTS) T. cruzi antigens. For prophylactic vaccination, naïve C57BL/6 mice were immunized with rAdASP2+rAdTS (rAdVax) using a homologous prime/boost protocol before challenge with the Colombian strain. For therapeutic vaccination, rAdVax administration was initiated at 120 days post-infection (dpi), when mice were afflicted by CCC. Mice were analyzed for electrical abnormalities, immune response and cardiac parasitism and tissue damage. Prophylactic immunization with rAdVax induced antibodies and H-2K(b)-restricted cytotoxic and interferon (IFN)γ-producing CD8(+) T-cells, reduced acute heart parasitism and electrical abnormalities in the chronic phase. Therapeutic vaccination increased survival and reduced electrical abnormalities after the prime (analysis at 160 dpi) and the boost (analysis at 180 and 230 dpi). Post-therapy mice exhibited less heart injury and electrical abnormalities compared with pre-therapy mice. rAdVax therapeutic vaccination preserved specific IFNγ-mediated immunity but reduced the response to polyclonal stimuli (anti-CD3 plus anti-CD28), CD107a(+) CD8(+) T-cell frequency and plasma nitric oxide (NO) levels. Moreover, therapeutic rAdVax reshaped immunity in the heart tissue as reduced the number of perforin+ cells, preserved the number of IFNγ(+) cells, increased the expression of IFNγ mRNA but reduced inducible NO synthase mRNA. Vaccine-based immunostimulation with rAd might offer a rational alternative for re-programming the immune response to preserve and, moreover, recover tissue injury in Chagas’ heart disease. Public Library of Science 2015-01-24 /pmc/articles/PMC4305326/ /pubmed/25617628 http://dx.doi.org/10.1371/journal.ppat.1004594 Text en © 2015 Pereira et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Pereira, Isabela Resende
Vilar-Pereira, Glaucia
Marques, Virgínia
da Silva, Andrea Alice
Caetano, Bráulia
Moreira, Otacilio Cruz
Machado, Alexandre Vieira
Bruna-Romero, Oscar
Rodrigues, Maurício Martins
Gazzinelli, Ricardo Tostes
Lannes-Vieira, Joseli
A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title_full A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title_fullStr A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title_full_unstemmed A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title_short A Human Type 5 Adenovirus-Based Trypanosoma cruzi Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy
title_sort human type 5 adenovirus-based trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305326/
https://www.ncbi.nlm.nih.gov/pubmed/25617628
http://dx.doi.org/10.1371/journal.ppat.1004594
work_keys_str_mv AT pereiraisabelaresende ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT vilarpereiraglaucia ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT marquesvirginia ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT dasilvaandreaalice ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT caetanobraulia ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT moreiraotaciliocruz ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT machadoalexandrevieira ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT brunaromerooscar ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT rodriguesmauriciomartins ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT gazzinelliricardotostes ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT lannesvieirajoseli ahumantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT pereiraisabelaresende humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT vilarpereiraglaucia humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT marquesvirginia humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT dasilvaandreaalice humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT caetanobraulia humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT moreiraotaciliocruz humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT machadoalexandrevieira humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT brunaromerooscar humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT rodriguesmauriciomartins humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT gazzinelliricardotostes humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy
AT lannesvieirajoseli humantype5adenovirusbasedtrypanosomacruzitherapeuticvaccinereprogramsimmuneresponseandreverseschroniccardiomyopathy